Page last updated: 2024-11-02

pirenzepine and Fatty Liver

pirenzepine has been researched along with Fatty Liver in 2 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, X1
Zhao, Y1
Shao, H1
Zheng, X1
Haberfellner, EM1
Honsig, T1

Other Studies

2 other studies available for pirenzepine and Fatty Liver

ArticleYear
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.
    Psychoneuroendocrinology, 2019, Volume: 108

    Topics: Animals; Benzodiazepines; Blood Glucose; Body Weight; Dyslipidemias; Energy Metabolism; Fatty Liver;

2019
Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:7

    Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Benzodiazepines; Fat

2003